Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IKT
stocks logo

IKT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2026Q1
--
--
-0.130
-80%
--
--
-0.180
+20%
Estimates Revision
The market is revising No Change the revenue expectations for Inhibikase Therapeutics, Inc. (IKT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -9.58%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-9.58%
In Past 3 Month
Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.510
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 1.510
sliders
Low
8.00
Averages
8.00
High
8.00
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-28
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Strong Buy
to
Hold
Downgrades
n/a
2025-02-12
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-02-12
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT.O) is -2.14, compared to its 5-year average forward P/E of -3.30. For a more detailed relative valuation and DCF analysis to assess Inhibikase Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.30
Current PE
-2.14
Overvalued PE
-0.24
Undervalued PE
-6.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.89
Current PS
0.00
Overvalued PS
62.84
Undervalued PS
-9.05
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IKT News & Events

Events Timeline

(ET)
2025-11-20
22:55:43
Inhibikase Therapeutics Prices 46.1M Share Spot Secondary at $1.45
select
2025-11-20
16:48:21
Inhibikase Therapeutics Announces Secondary Offering Price of $1.45
select
2025-11-20
16:14:35
Inhibikase Reveals Offering of Common Stock and Warrants, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-21Benzinga
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading

  • Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.

  • Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.

  • Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.

  • Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.

[object Object]
Preview
5.0
08-19Newsfilter
Inhibikase Therapeutics Enhances Leadership with Timothy Pigot's Appointment as Chief Commercial and Strategy Officer

  • New Appointment: Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer, bringing extensive experience in the pharmaceutical industry, particularly in pulmonary arterial hypertension (PAH).

  • Leadership Insight: CEO Mark Iwicki expressed confidence in Pigot's expertise and connections within the PAH market, which will be crucial as the company advances its lead product candidate, IKT-001, towards late-stage clinical trials.

  • Company Background: Inhibikase Therapeutics focuses on developing therapies for cardiopulmonary diseases, specifically targeting PAH, a serious condition affecting around 50,000 Americans.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future activities and potential risks that could impact their progress and results.

[object Object]
Preview
9.5
08-15Newsfilter
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

  • Company Developments: Inhibikase Therapeutics is advancing its lead product candidate, IKT-001, towards a Phase 2b clinical trial for Pulmonary Arterial Hypertension (PAH), with study initiation expected in the second half of 2025. The trial will evaluate different dosages of IKT-001 compared to placebo in approximately 150 participants.

  • Financial Overview: For the quarter ending June 30, 2025, Inhibikase reported a net loss of $9.9 million and cash reserves of $87.7 million, reflecting an increase in research and development expenses due to the acquisition of CorHepta and ongoing clinical trials.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Inhibikase Therapeutics Inc (IKT) stock price today?

The current price of IKT is 1.51 USD — it has increased 4.86 % in the last trading day.

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s business?

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

arrow icon

What is the price predicton of IKT Stock?

Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s revenue for the last quarter?

Inhibikase Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s earnings per share (EPS) for the last quarter?

Inhibikase Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -80.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Inhibikase Therapeutics Inc (IKT)'s fundamentals?

The market is revising No Change the revenue expectations for Inhibikase Therapeutics, Inc. (IKT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -9.58%.
arrow icon

How many employees does Inhibikase Therapeutics Inc (IKT). have?

Inhibikase Therapeutics Inc (IKT) has 15 emplpoyees as of December 05 2025.

arrow icon

What is Inhibikase Therapeutics Inc (IKT) market cap?

Today IKT has the market capitalization of 183.72M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free